Abbott Laboratories (NYSE:ABT) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Abbott Laboratories (NYSE:ABT) had its target price hoisted by research analysts at Wells Fargo & Company from $112.00 to $119.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the healthcare product maker’s stock. Wells Fargo & Company’s target price would suggest a potential upside of 17.22% from the company’s current price.

ABT has been the subject of a number of other research reports. Barclays started coverage on Abbott Laboratories in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target for the company. UBS Group reduced their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Robert W. Baird lifted their target price on shares of Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research note on Thursday. Piper Sandler restated an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $118.12.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded up $1.01 during mid-day trading on Thursday, hitting $101.52. The company had a trading volume of 2,579,517 shares, compared to its average volume of 11,288,301. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $175.66 billion, a price-to-earnings ratio of 32.76, a P/E/G ratio of 1.90 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02. The stock’s 50-day moving average price is $105.47 and its 200-day moving average price is $98.28.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting the consensus estimate of $1.42. The firm had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The company’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.30 earnings per share. On average, sell-side analysts forecast that Abbott Laboratories will post 5.53 earnings per share for the current year.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ledyard National Bank boosted its position in shares of Abbott Laboratories by 6.4% in the 3rd quarter. Ledyard National Bank now owns 15,237 shares of the healthcare product maker’s stock worth $1,506,000 after purchasing an additional 913 shares in the last quarter. Culbertson A N & Co. Inc. raised its stake in Abbott Laboratories by 0.3% during the third quarter. Culbertson A N & Co. Inc. now owns 90,195 shares of the healthcare product maker’s stock valued at $8,914,000 after buying an additional 270 shares during the last quarter. NBT Bank N.A. bought a new stake in Abbott Laboratories in the third quarter worth $9,060,000. Root Financial Partners LLC grew its stake in shares of Abbott Laboratories by 93.7% in the third quarter. Root Financial Partners LLC now owns 7,430 shares of the healthcare product maker’s stock worth $734,000 after acquiring an additional 3,594 shares during the last quarter. Finally, Precedent Wealth Partners LLC increased its holdings in shares of Abbott Laboratories by 10.7% during the third quarter. Precedent Wealth Partners LLC now owns 33,354 shares of the healthcare product maker’s stock valued at $3,296,000 after acquiring an additional 3,234 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter performance was broadly solid: adjusted earnings were $1.42 per share, in line with consensus, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding estimates. Comparable sales increased 7%. Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Analysts remain constructive despite trimming some targets. Robert W. Baird raised its target to $123, while BTIG, JPMorgan and TD Cowen maintained buy-equivalent ratings with targets ranging from $118 to $125, implying meaningful upside from recent levels.
• Positive Sentiment: Abbott received European regulatory clearance for Cologuard Plus, expanding the potential market for its noninvasive colorectal-cancer screening test. Cologuard Plus European approval
• Neutral Sentiment: Abbott plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Pedialyte, PediaSure and Glucerna—into an independent, publicly traded company through a tax-free distribution to shareholders by the end of 2027. Management expects the transaction to give both companies more focused growth strategies, though investors must assess execution and the future value of the separated businesses. Abbott Nutrition spinoff announcement
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing diabetes-related pricing pressure and weakness in electrophysiology and other medical-device areas. That guidance reduction overshadowed the quarterly revenue performance and caused the stock to decrease after the announcement. Reuters Abbott outlook report
• Negative Sentiment: Although adjusted EPS matched the broader consensus, some services reported a modest miss against the higher Zacks estimate of $1.43. Combined with the lower sales outlook and uncertainty around the spinoff, this has increased near-term investor caution.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.